As­traZeneca, Dai­ichi Sankyo claim PhI­II lung can­cer win for their next big ADC — but shares fall

As­traZeneca and Dai­ichi Sankyo’s multi­bil­lion-dol­lar an­ti­body-drug con­ju­gate al­liance has gen­er­at­ed a Phase III win, the part­ners say, beef­ing up the case that they have a broad­ly ap­plic­a­ble lung can­cer drug in the pipeline.

But a vague men­tion of pa­tient deaths and the ab­sence of more en­thu­si­as­tic lan­guage is spurring ques­tions and has cast a shad­ow on the os­ten­si­bly pos­i­tive topline re­sults. As­traZeneca shares $AZN trad­ed down about 6% both on the Lon­don stock ex­change and pre­mar­ket on the Nas­daq.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER